In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long …
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid …
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid resulted in no drug-related adverse events and rapid reduction in …
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Poster to be presented on back-of-the-eye program including data from uveitis preclinical modelInterim data expected from Akari’s Phase I/II clinical trial in …
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 – Akari Therapeutics, Plc …
